Together, the present study combining bioinformatic analysis with the several biochemical functional analyses in vitro and in vivo, provided strong supports for the hypothesis that SCARA3 is a potential target for the treatment of obesity and other metabolic disorders. Here, SCARA3 is linked to Other metabolic disease.